Asia Invests in Laboratory Tools for Medicinal Chemistry
News May 01, 2006
Radleys has announced sales of its parallel chemistry and laboratory reactor products have contributed to a 400% growth in its Asian business during 2004-5 and 2005-6.
Reflecting on the spectacular business growth, Mark Radley (Managing Director) commented, "In recent years a growing proportion of our traditional pharmaceutical and biotech industry customers in Europe and North America have started to relocate part of their R&D to Asia."
"Consequently we have increased our resource allocation to the region and have seen companies including SABIC, Nicholas Piramal, Altana, GVK, Syngene, Dr Reddys, Advinus and Torrent investing in technology such as the Carousel, GreenHouse and Lara product ranges, to enable them to either win contracts from US or European pharma/biotech companies or to develop their own R&D programs."
Key Ingredient in Diabetes Drug Modified to Improve Side EffectsNews
Improved medications for Type 2 diabetes are one step closer thanks to a new discovery reported this week. By modifying the key ingredient in current diabetes drugs, the researchers produced a compound that was effective for hyperglycemia in animal trials, yet without the most problematic side effects of current drugs.READ MORE
Tackling Cancer at Ground Zero: Designer Molecule Inhibits Protein TargetNews
A new molecule designed by University of Adelaide researchers shows great promise for future treatment of many cancers. The new molecule successfully targets a protein that plays a major role in the growth of most cancers.READ MORE